Bristol-Myers Squibb: A Gem In A Period Of Macroeconomic Uncertainties
The company''s medicines received over 10 regulatory approvals in Europe, Japan, and the US in the first half of 2022. Read more to see our price target on BMY.
Bristol-Myers Squibb: A Gem In A Period Of Macroeconomic Uncertainties
The company''s medicines received over 10 regulatory approvals in Europe, Japan, and the US in the first half of 2022. Read more to see our price target on BMY.